Search

Issue
Title
Authors
New chemotherapy options for triple-negative breast cancer (review of literature)
Sekundova M.A., Zdvizhkov A.M., Borisov V.I.
Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study
Evdokimov V.I., Bloshchinenko A.A., Abolmasov A.E., Vilensky A.A., Laskov M.S.
Breast cancer: genetic personal risk factors: A review
Zolotykh M.A., Bilyalov A.I., Nesterova A.I., Gimranov A.M., Filina J.V., Rizvanov A.A., Miftakhova R.R.
Innovations in practice. 5 years of palbociclib experience in the Russian Federation. Overview of web-conference took place on 8 October 2021
Editorial B.
Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer
Samaneva N.I., Vladimirova L.I., Kolyadina I.V., Frantsiyants E.M., Storozhakova A.E., Bandovkina V.A., Kalabanova E.A., Kabanov S.N., Svetitskaya I.V., Tishina A.V., Ezhova M.O.
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
Kovalenko E.I., Artamonova E.V., Karabina E.V., Andreiashkina I.I., Prokof’eva E.A., Popova N.O., Gaisina E.A., Evstigneeva I.V., Shaidorov M.V., Zhiliaeva L.A., Ponomarenko D.M., Khasanova A.I., Mukhametshina G.Z., Koziakov A.E., Vorotilina L.V., Povyshev A.I., Simolina E.I., Marfutov V.V., Kozlov D.V., Suslova I.R., Shikina V.E., Karandeeva T.V., Shepel’ A.O., Kramskaia L.V., Oskirko D.A., Frolova O.S.
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
Gorbunova V.A., Kolyadina I.V., Kovalenko E.I., Manziuk L.V., Artamonova E.V., Zhukova L.G., Bolotina L.V., Semiglazova T.I., Manikhas A.G., Raevskaia N.A., Itkin I.M., Filonenko D.V., Zhilyaeva L.A., Gol'dberg V.E., Popova N.O., Ponomarenko D.M., Shikina V.E., Suslova I.R., Romanchuk O.V., Kozlov D.V., Rzaev A.S., Marfutov V.V., Andreiashkina I.I., Vladimirova L.I., Mitashok I.S., Tikhanovskaia N.M., Karabina E.V., Mukhametshina G.Z., Khasanova A.I., Safina S.Z., Shaidorov M.V., Morozov D.A., Prokof'eva E.P., Kramskaia L.V., Karandeeva T.V., Evstigneeva I.V., Ovchinnikova E.G., Klement'eva T.P., Khrupalo O.V., Tiuvinova E.V., Sherstnev V.M., Chernov I.S., Kolokolov D.D., Gaisina E.A., Levchenko N.V., Chubenko V.A., Povyshev A.I., Iudina I.V., Vorotilina L.V., Andreeva T.V., Tumanian G.S., Koziakov A.E., Gil'mutdinova L.A., Osipov M.A., Shatokhina A.S., Vazhenina A.A., Chichkanova A.S., Vladimirov V.I., Ivanov A.N., Belokhvostova A.S., Cherniakova E.M., Tul'china E.A., Maklashova S.A., Shkodenko O.N., Kostalanova I.V., Tarasova A.V., Kuz'mina E.S.
Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
Kolbin A.S., Mosikyan A.A., Balykina Y.E., Proskurin M.A.
PARP inhibitors in female reproductive system cancers
Pokataev I.A., Tyulyandin S.A.
The role of nab-paclitaxel in the treatment of patients with metastatic breast cancer
Frolova M.A.
The results of Epidemiological HER2 screening program in patients with breast cancer in 2014
Poddubnaya I.V., Frank G.A., Yagudina R.I., Koroleva N.I., Zavalishina L.E.
Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial
Ahmetzanov F.S., Ahmetzanova F.F.
Bone mineral density in patient with breast cancer
Poddubnaya I.V., Kizhaev E.V., Kolyadina I.V., Banov S.M., Zhmaeva E.M., Secko M.A.
Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
Grechukhina K.S., Filonenko D.A., Sukhova M.V., Zhukova L.G.
The effect of hormonal contraception on the risk of breast cancer: A review
Iurova M.V., Mezhevitinova E.A., Yakushevskaya O.V., Rodionov V.V., Prilepskaya V.N.
Interrelation of HLA-I and class II major histocompatibility complex molecules with clinical and morphological signs of breast cancer: A retrospective cohort study
Chulkova S.V., Sholokhova E.N., Poddubnaya I.V., Stilidi I.S., Burov D.A., Tupitsyn N.N.
Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study
Savelyeva M.I., Golubenko E.O., Sozaeva Z.A., Poddubnaya I.V., Korennaya V.V.
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III
Morozov D.A., Kolyadina I.V., Poddubnaya I.V., Ganshina I.P., Khokhlova S.V., Kоmetova V.V., Rodionov V.V.
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
Kolyadina I.V., Abidova N.R., Akopyan A.A., Antonova G.V., Arapova O.I., Bobrova E.A., Bolotina L.V., Valiakhmetova C.K., Vasilevskaya A.V., Vladimirova L.Y., Volkonskiy M.V., Ganshina I.P., Gudkova I.E., Dergunov A.S., Evstigneeva I.V., Egurenkova V.S., Emshanov A.V., Zhukova L.G., Zueva E.V., Karabina E.V., Kolokolov J.J., Kuzmicheva S.V., Kuchevskaya O.A., Luev I.A., Maistrenko K.S., Markizova E.V., Marfutov V.V., Medvedev S.P., Merzlikina Y.I., Nersesova T.A., Ovchinnikova E.G., Orlova S.A., Samaneva N.Y., Stativko O.A., Storozhakova A.E., Stroyakovskiy D.L., Sultanbaev A.V., Tekeeva A.I., Fadeeva N.V., Fedorova A.N., Shalaeva O.M., Shangina I.A., Shirokova O.N., Shumskikh A.R., Yakubova M.Z.
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor
Ganshina I.P., Ivanova K.A., Lubennikova E.V., Arkhipov A.V., Zhukova L.G.
The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience
Kolyadina I.V., Bulavina I.S., Petkau V.V., Strakhova N.V., Gorbunova V.A., Kovalenko E.I., Manziuk L.V., Artamonova E.V., Zhukova L.G., Bolotina L.V., Gan'shina I.P., Semiglazova T.I., Manikhas A.G., Raevskaia N.A., Itkin I.M., Khokhlova S.V., Filonenko D.V., Gol'dberg V.E., Popova N.O., Ponomarenko D.M., Shikina V.E., Vladimirova L.I., Tikhanovskaia N.M., Karabina E.V., Mukhametshina G.Z., Khasanova A.I., Safina S.Z., Shaidorov M.V., Orlov A.E., Kostalanova I.V., Levchenko N.V., Osipov M.A., Karandeeva T.V., Evstigneeva I.V., Chernov I.S., Kolokolov D.D., Povyshev A.I., Shatokhina A.S., Cherniakova E.M., Shkodenko O.N., Kuz'mina E.S.
The effect of derivatives of 3-hydroxypyridine and succinic acids on depressive symptoms, pain intensity and quality of life after surgical treatment of breast cancer
Volchegorskii I.A., Vazhenin A.V., Zyuzina M.S.
Pharmacoeconomic characteristics of ixabepilone (Ixempra) monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
Kolbin A.S., Mosikyan A.A., Kurilev A.A., Balykina Y.E., Proskurin M.A.
The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
Bolotina L.V., Manziuk L.V., Gorbunova V.A., Kovalenko E.I., Mukhametshina G.Z., Khasanova A.I., Vladimirova L.Y., Mitashok I.S., Prokofyeva E.P., Evstigneeva I.V., Andreyashkina I.I., Abramova N.A., Popova I.L., Karabina E.V., Teterich A.A., Gaysina E.A., Chubenko V.A., Limareva S.V., Tikhanovskaya N.M., Storozhakova A.E., Samaneva N.Y., Svetitskaya Y.V., Snezhko T.A., Kalabanova E.A.
Neoadjuvant systemic therapy of HER2-positive breast cancer
Frolova M.A.
Skin sparing mastectomy
Ovchinnikov M.V., Egorov Y.S.
The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature)
Semiglazov V.F., Semiglazov V.V., Paltuev P.M., Nikolaev K.S., Dashyan G.A.
Evolution of anti-HER2 therapy in advanced HER2+ breast cancer or “why is trastuzumab still a key player?”. A review
Grechukhina K.S., Sukhova M.V., Kolyago E.M., Filonenko D.A., Zhukova L.G.
Scalp hypothermia for the prevention of chemotherapy-induced alopecia in breast cancer
Ognerubov N.A., Barsukov S.V.
Membrane (CD8⁺PD-1⁺ and CD4+PD-1⁺) and soluble (sPD-1 and sPD-L1) forms of immune checkpoints in melanoma, breast cancer, and oral mucosal cancer patients: A observational study
Zabotina T.N., Chertkova A.I., Borunova A.A., Kushlinskii N.E., Gershtein E.S., Zakharova E.N., Shoua E.K., Tsiklauri V.T., Samoylenko I.V., Khoroshilov M.V., Kadagidze Z.G.
Clinical factors of the risk of hyperplastic endometry processes on tamoxifen therapy with breast cancer: Retrospective population study
Golubenko E.O., Savelyeva M.I., Poddubnaya I.V., Korennaya V.V.
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
Shlivko I.L., Garanina O.E., Artamonova E.V., Ganshina I.P., Zhukova L.G., Koroleva I.A., Michenko A.V., Semiglazova T.Y., Filonenko D.A.
The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia
Sokolova T.N., Aleksakhina S.N., Yanus G.A., Sultanbaev A.V., Menshikov K.V., Lysenko A.N., Zukov R.A., Zyuzyukina A.V., Murunova Y.N., Rossokha E.I., Bakharev S.Y., Basova E.A., Kasmynina T.A., Shumskaya I.S., Bakshun Y.I., Musaeva K.S., Khasanova A.I., Dmitriev V.N., Bolieva M.B., Gadzaova C.H., Petrenko O.L., Maksimov D.A., Vladimirov V.I., Goldberg V.E., Popova N.O., Kibisheva M.V., Khamgokov Z.M., Vasilyev A.E., Iyevleva A.G., Imyanitov E.N.
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
Ganshina I.P., Gordeeva O.O., Manukian M.S.
Dermatomyositis and polymyositis in breast cancer patients: a case reports
Ganshina I.P., Zhukova L.G., Burnevitch E.Z., Gordeeva O.O., Kondratieva O.E.
Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study
Ignatova E.O., Burdaeva O.N., Kopp M.V., Kotiv B.N., Udovitsa D.P., Stroiakovskii D.L., Alekseev S.M., Sheveleva L.P., Khorinko A.V., Shapovalova I.S., Moiseenko V.M., Ivanov R.A.
Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy
Krivorotko P.V., Burdaeva O.N., Nechaeva M.N., Frolova M.A., Kopp M.V., Abrosimova A.A., Ivanov R.A.
Quality of life is the fundamental criterion of the efficacy of targeted therapy in patients with metastatic Her2-positive breast cancer
Semiglazova T.Y., Dashyan G.A., Semiglazov V.V., Zhabina A.S., Osipov M.A., Kotova Z.S., Klimenko V.V., Krivorotko P.V., Semiglazov V.F.
Personalized approach to HER2-positive advanced breast cancertherapy
Stenina M.B.
101 - 139 of 139 Items << < 1 2 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"